Literature DB >> 23725320

Colonisation by Faecalibacterium prausnitzii and maintenance of clinical remission in patients with ulcerative colitis.

E Varela1, C Manichanh, M Gallart, A Torrejón, N Borruel, F Casellas, F Guarner, M Antolin.   

Abstract

BACKGROUND: Although incrimination of the intestinal microbiota in the pathogenesis of IBD is widely accepted, few data are available about the role of specific bacteria. Potentially, Faecalibacterium prausnitzii, bacteria with anti-inflammatory properties, might be deficient in ulcerative colitis (UC). AIM: To quantify F. prausnitzii in the faecal microbiota of UC patients in remission and determine its relationship with relapse.
METHODS: A cross-sectional study included 116 UC patients in remission, 29 first-degree relatives and 31 healthy controls. A subset of eighteen patients, recruited during the first month of remission, underwent a 1-year follow-up. Total bacteria and F. prausnitzii were measured by quantitative Real Time PCR (qPCR, copies/g). Calprotectin was determined as inflammatory index (μg/g).
RESULTS: We found that F. prausnitzii was reduced in patients (median, IQR: 1.4 × 10⁸ , 5.1 × 10⁷-4.5 × 10⁸) and relatives (1.7 × 10⁸, 9.3 × 10⁷-5.1 × 10⁸) vs. controls (6.5 × 10⁸, 3.7 × 10⁸-1.6 × 10⁹, P < 0.0001). Moreover, low counts of F. prausnitzii were associated with less than 12 months of remission (8.0 × 10⁷, 2.0 × 10⁷-3.5 × 10⁸ vs. 2.1 × 10⁸, 1.0 × 10⁸-7.9 × 10⁸, P < 0.001) and more than 1 relapse/year (8.0 × 10⁷, 3.2 × 10⁷-3.8 × 10⁸ vs. 1.9 × 10⁸, 6.8 × 10⁷-6.0 × 10⁸, P < 0.01). When patients were followed up, F. prausnitzii increased steadily until reaching similar levels to those of controls if remission persisted (2.9 × 10⁸, 9.3 × 10⁶-1.2 × 10⁹; calprotectin: 76, 19-212), whereas it remained low if patients relapsed (2.2 × 10⁸, 1.4 × 10⁶-3.3 × 10⁸; calprotectin: 1760, 844-3662 P < 0.05 vs. controls).
CONCLUSIONS: Defective gut colonisation by F. prausnitzii occurred in UC patients during remission and in their unaffected relatives. The recovery of the F. prausnitzii population after relapse is associated with maintenance of clinical remission.
© 2013 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23725320     DOI: 10.1111/apt.12365

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  83 in total

Review 1.  The gut microbiome: what every gastroenterologist needs to know.

Authors:  Benjamin H Mullish; Mohammed Nabil Quraishi; Jonathan P Segal; Gianluca Ianiro; Tariq H Iqbal
Journal:  Frontline Gastroenterol       Date:  2020-02-04

2.  Ecology and metabolism of the beneficial intestinal commensal bacterium Faecalibacterium prausnitzii.

Authors:  Sylvie Miquel; Rebeca Martín; Chantal Bridonneau; Véronique Robert; Harry Sokol; Luis G Bermúdez-Humarán; Muriel Thomas; Philippe Langella
Journal:  Gut Microbes       Date:  2014-01-22

Review 3.  Fecal microbiota transplantation: in perspective.

Authors:  Shaan Gupta; Emma Allen-Vercoe; Elaine O Petrof
Journal:  Therap Adv Gastroenterol       Date:  2016-03       Impact factor: 4.409

Review 4.  The microbiome in inflammatory bowel disease: current status and the future ahead.

Authors:  Aleksandar D Kostic; Ramnik J Xavier; Dirk Gevers
Journal:  Gastroenterology       Date:  2014-02-19       Impact factor: 22.682

Review 5.  Immunological mechanisms underpinning faecal microbiota transplantation for the treatment of inflammatory bowel disease.

Authors:  M N Quraishi; W Shaheen; Y H Oo; T H Iqbal
Journal:  Clin Exp Immunol       Date:  2019-11-27       Impact factor: 4.330

6.  The gut microbiome composition associates with bipolar disorder and illness severity.

Authors:  Simon J Evans; Christine M Bassis; Robert Hein; Shervin Assari; Stephanie A Flowers; Marisa B Kelly; Vince B Young; Vicky E Ellingrod; Melvin G McInnis
Journal:  J Psychiatr Res       Date:  2016-12-10       Impact factor: 4.791

Review 7.  Mucosal healing and deep remission: what does it mean?

Authors:  Gerhard Rogler; Stephan Vavricka; Alain Schoepfer; Peter L Lakatos
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

Review 8.  The gut microbiota in IBD.

Authors:  Chaysavanh Manichanh; Natalia Borruel; Francesc Casellas; Francisco Guarner
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-08-21       Impact factor: 46.802

Review 9.  Environmental risk factors for inflammatory bowel diseases: Evidence based literature review.

Authors:  Ayokunle T Abegunde; Bashir H Muhammad; Owais Bhatti; Tauseef Ali
Journal:  World J Gastroenterol       Date:  2016-07-21       Impact factor: 5.742

10.  Association of Systemic Sclerosis With a Unique Colonic Microbial Consortium.

Authors:  Elizabeth R Volkmann; Yu-Ling Chang; Nashla Barroso; Daniel E Furst; Philip J Clements; Alan H Gorn; Bennett E Roth; Jeffrey L Conklin; Terri Getzug; James Borneman; Dermot P B McGovern; Maomeng Tong; Jonathan P Jacobs; Jonathan Braun
Journal:  Arthritis Rheumatol       Date:  2016-06       Impact factor: 10.995

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.